• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NovaBay Pharmaceuticals Launches DERMAdoctor's New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on the QVC® Network

    4/21/23 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBY alert in real time by email

    First DERMAdoctor product specifically formulated for psoriasis will be exclusively available on Jane & Shawn's Beauty Secrets tonight at 10 p.m. Eastern time

    NovaBay Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer and board-certified dermatologist Audrey Kunin, MD will introduce the new DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream with 3% Salicylic Acid as an on-air guest on the QVC network. The new product for the treatment and relief of symptoms of psoriasis will be featured on Jane & Shawn's Beauty Secrets tonight at 10 p.m. Eastern time.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230421005008/en/

    DERMAdoctor® Psoriasis Therapeutic Moisturizing Cream with 3% Salicylic Acid (Photo: Business Wire)

    DERMAdoctor® Psoriasis Therapeutic Moisturizing Cream with 3% Salicylic Acid (Photo: Business Wire)

    Psoriasis Therapeutic Moisturizing Cream with 3% Salicylic Acid will be available exclusively on QVC through a special offer of two 8 fluid ounce size tubes for $52. This product will be available on DERMAdoctor.com and Amazon for $46 for a single tube beginning July 31, 2023.

    "Psoriasis afflicts about 125 million people worldwide and nearly 8 million in the U.S., with more than half reporting that psoriasis is a significant problem in their everyday life," said Dr. Kunin. "We are thrilled to introduce our first specially formulated product to provide relief from the itching, scaling, redness, flaking and irritation caused by psoriasis on QVC. Our new luxe moisturizing cream contains salicylic acid to relieve and prevent the recurrence of psoriasis symptoms, while helping to restore skin's essential moisture for a soft, supple, comfortable and joy-filled appearance."

    Psoriasis Therapeutic Moisturizing Cream with 3% Salicylic Acid delivers a sophisticated blend of maximum-strength salicylic acid – the active ingredient that helps control the symptoms of psoriasis and provides relief from itching, irritation and redness – together with ceramides to help protect and preserve the skin barrier to keep in vital moisture, hyaluronic acid to draw moisture from the air to keep skin feeling plump and hydrated, and squalene to help moisturize skin. Steroid-free and fragrance-free, this clean formulation is appropriate for even the most sensitive skin from head to toe.

    Dr. Kunin is an author, clinician, educator, television personality and recognized trailblazer in the skincare industry. DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns that have been overlooked by the beauty industry. DERMAdoctor delivers on the promise that clinical skin therapy can be simple and easy. All DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns that have been largely overlooked by the beauty industry and are hypoallergenic, non-irritating, non-drying, pH balanced and free of synthetic fragrance and dyes.

    About Psoriasis

    Psoriasis is an immune-mediated condition that causes the body to make new skin cells in days rather than weeks. Anyone can get this disease, regardless of age; however, it often has two peaks of onset with the first between age 20-30 and the second between age 50-60. Males and females get it at about the same rate. Psoriasis can show up anywhere on the body including eyelids, ears, mouth, lips, skin folds, hands, feet and nails.

    About NovaBay Pharmaceuticals, Inc.:

    NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay's leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.

    NovaBay Pharmaceuticals Forward-Looking Statements

    Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company's expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company's cash needs. Other risks relating to NovaBay's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

    Socialize and Stay Informed on NovaBay's Progress

    Like us on Facebook

    Follow us on Twitter

    Connect with NovaBay on LinkedIn

    Visit NovaBay's Website

    Avenova Purchasing Information

    For NovaBay Avenova purchasing information:

    Please call 800-890-0329 or email [email protected]

    Avenova.com

    DERMAdoctor Purchasing Information

    For DERMAdoctor purchasing information:

    Please call 877-337-6237 or email [email protected]

    DERMAdoctor.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005008/en/

    Get the next $NBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBY
    SEC Filings

    View All

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Other Events

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    1/30/26 5:09:15 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by NovaBay Pharmaceuticals Inc.

    PRE 14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    1/30/26 5:03:33 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    1/28/26 4:10:37 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lazar David E. was granted 6,388,000 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    1/29/26 7:30:12 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Framework Ventures Iv L.P. converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:39:23 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner R01 Fund Lp converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:38:56 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

    EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's continued listing standards. As previously disclosed, the NYSE American notified the Company on April 18, 2024 and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide. Specifically, the notifications indicated that the Company was not in compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company guide, requiring a listed company to have stockholders' equity of at least $6 million. Following the issuance and sale of p

    10/20/25 7:07:28 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:50:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:46:27 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:40:59 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    11/8/24 5:31:40 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/14/24 2:52:33 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/13/24 5:17:39 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innovations in Disinfection Technology Aid the Return of Workers

    NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

    12/9/20 9:00:00 AM ET
    $NBY
    $CEMI
    $BSGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $NBY
    Financials

    Live finance-specific insights

    View All

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

    EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders

    8/19/25 5:25:32 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

    8/1/24 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care